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Summary
Cancer stem cells are rare tumor cells characterized by
their ability to self-renew and to induce tumorigenesis.
They are present in gliomas and may be responsible
for the lethality of these incurable brain tumors. In
the most aggressive and invasive type, glioblastoma
multiforme (GBM), an average of about one year spans
the period between detection and death [1]. The resis-
tence of gliomas to current therapies may be related to
the existence of cancer stem cells [2–6]. We find that
human gliomas display a stemness signature and
demonstrate that HEDGEHOG (HH)-GLI signaling
regulates the expression of stemness genes in and
the self-renewal of CD133+ glioma cancer stem cells.
HH-GLI signaling is also required for sustained glioma
growth and survival. It displays additive and synergis-
tic effects with temozolomide (TMZ), the current che-
motherapeutic agent of choice. TMZ, however, does
not block glioma stem cell self-renewal. Finally, inter-
ference of HH-GLI signaling with cyclopamine or
through lentiviral-mediated silencing demonstrates
that the tumorigenicity of human gliomas in mice re-
quires an active pathway. Our results reveal the essen-
tial role of HH-GLI signaling in controlling the behavior
of human glioma cancer stem cells and offer new ther-
apeutic possibilities.
Results and Discussion
Previous work provided evidence for a role of HH-GLI
signaling in gliomas [7]. SONIC HEDGEHOG (SHH) acti-
vates a signal-transduction cascade that includes the
action of the membrane proteins PATCHED1 (PTCH1)
and SMOOTHENED (SMOH), leading to the action of
GLI transcription factors [8]. Analyses of a panel of fresh
brain tumors (Figure 1A, Table S1 in the Supplemental
Data available online) demonstrated the ubiquitous
and varied expression of HH-GLI pathway components
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presence of an active pathway (Figure 1A, Figures S1A–
S1C and Figure S2) because GLI1 transcription is the
only reliable marker of pathway activity. GLI1 was the
only gene overexpressed on average in all tumor types,
as judged on the basis of the average expression levels
of three separate cortical regions of normal brain tissue.
PTCH1 levels were lower in glioblastoma multiformes
(GBMs) [9], and SHH was high only in a subset of low-
grade gliomas. Although some gliomas express SHH in
tumor cells [7], a subset with low expression localized
it in new vessels, whereasPTCH1was indeed expressed
in tumor cells ([7]; Figure 1B).
Gliomas showed a stemness signature (Figure 1A,
Figure S2) that included the expression of the stemness
genes NANOG, OCT4, SOX2, and BMI1, centered over
grade III gliomas but extending into neighboring grade
IV (GBM) and grade II tumors (Figure 1A). Tumors in tran-
sition may display a mixed character, such as a stem-
ness signature and multiforme appearance in GBM-4
and GBM-6 and low-grade pathology and a stemness
signature in some grade II tumors (Figure 1A). In con-
trast, there was only a poor correlation between grade
and a set of previously identified glioma prognostic
markers (Figure S3). Two medulloblastomas used as
controls [7] expressed GLI1 but did not overexpress
the same stemness gene set (Figure 1A). The stemness
signature of grade III gliomas suggests the abundance
of cancer stem cells in these tumors.
All but one adherent primary culture of gliomas tested
decreased cell proliferation as measured by BrdU in-
corporation after 48 hr treatment with cyclopamine,
a specific SMOH inhibitor [10], as compared with toma-
tidine as control (Figure 1C). Inhibition was dose depen-
dent and cumulative over time (Figure S4A). The GBM
cell line U87 behaved similarly (Figure 1C), decreased
GLI1 expression upon cyclopamine treatment (Fig-
ure S4B), and showed complete cell death after 10 days
of treatment (Figure S4C). However, drug removal after
5 days allowed culture recovery, indicating temporally
distinct cytostatic and cytotoxic effects (Figure S4C).
GLI RNA interference [11] demonstrated the general
requirement of GLI1 and GLI2 in brain tumor-cell prolif-
eration, with GLI1 knockdown having the strongest
effects, as compared with an unrelated siRNA control
(Figure 1D). As for prostate tumors [11], most brain
tumors tested had activation of the HH-GLI pathway at
the level of SMOH in the membrane or above. However,
because the one tumor that was insensitive to cyclop-
amine responded to GLI1 interference (Figure 1D), acti-
vation here likely took place on or downstream of
SMOH. The levels of inhibition reflected lipofection effi-
ciencies, and an independent set of siRNAs gave similar
results (Figures S5A and S5B). Interference with GLI1
and GLI2 also increased apoptosis (Figure 1F). Long-
term silencing in U87 cells increased cell death after in-
terference with GLI1 but not GLI2 (Figure S5C), indicat-
ing their differential requirement for survival in these
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166Figure 1. Gene Expression in Human Gliomas and Requirement of HH-GLI Signaling
(A) Diagram of expression levels with white for expression within normal range, red for overexpression, and blue for underexpression. Normal
expression ranges and thresholds were established by quantifying the expression level of the 22 markers used in three samples of normal cortex
(Figure S2). Gliomas are ranked by grade and by gene-expression pattern as GBM, glioblastoma mulitforme or grade IV astrocytomas (all primary
GBMs); A, astrocytoma; OG, oligodendroglioma; and AG, anaplastic glioma. The roman numeral denotes World Health Organization grade, and
the arabic numeral denotes the tumor number within our series. Two medulloblastomas (MB) are used as controls for HH-GLI pathway activity
[7]. Domains of consistent (>50% of cases) GLI1 activity and of the stemness signature are boxed, and the names of the genes are highlighted.
(B) In situ hybridization of fresh-frozen OG-III-2 samples as indicated with an H&E (Hematoxylyn and Eosin) stain (right) as a control. Arrows point
to expression in vessels (asterisks). The scale bar represents 200 mm.
(C and D) Inhibition of glioma cell proliferation in primary adherent cultures (passages 1–3) of fresh tumors. Percent reduction in BrdU incorpo-
ration as a measure of cell division is shown as the ratio of the result of treatment with cyclopamine over the result of treatment with tomatidine
used as a control (C), or as the ratio of treatment with each specified GLI siRNA over an unrelated siRNA control (siC; [D]). Error bars are
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167cells. GLI3, in contrast, had positive effects in only a mi-
nority of cases (Figure 1D), consistent with its rare role
as a minor activator and its more common role as a major
repressor of GLI targets [8]. GLI3 was found to mediate
the effects of cyclopamine: Cells transfected with GLI3
siRNA or a control siRNA and then treated with this
drug showed that the antiproliferative and proapoptotic
effects of cyclopamine were reverted by inhibition of
GLI3 (Figures 1E and 1F).
To test for a possible role of HH-GLI signaling in can-
cer stem cells, we have used glioma stem cell cultures
(gliomaspheres) (Figures 2A and 2B), which self-renew
and mimic the original tumor after transplantation into
the brains of immunocompromised mice [5]. Treat-
ment with cyclopamine decreased their proliferation
and increased apoptosis in a concentration-dependent
manner (Figures 2C and 2D). Inhibition of cell prolifera-
tion was recapitulated by transduction with a recombi-
nant lentiviral vector expressing an shRNA specific for
SMOH (LV-shSMOH) after comparison with a control
lentiviral vector (LV-control) (Figure 2E). Inhibition of
SMOH mRNA by the LV-shSMOH was at 67% in U87
cells and at 66% in GBM-8 72 hr after transduction.
Long-term treatment and recovery assays showed
that 20, but not 10, days of treatment with cyclopamine
were sufficient to kill all gliomasphere cells because
the culture did not recover after an additional 20 days
without the drug (Figure S6E). In contrast, the DNA-
damaging chemotherapeutic agent temozolomide
(TMZ; [1]) also affected the proliferation and survival of
glioma cells (Figures S6A–S6D) but was unable to pre-
vent recovery (Figure S6F). Importantly, TMZ showed
additive or synergistic effects in different glioma stem
cell cultures and in U87 cells with an intermediate dose
(5 mM) of cyclopamine on the inhibition of cell prolifera-
tion and the enhancement of apoptosis (Figures 2F
and 2G).
Intracraneal xenografts of untransduced or LacZ-
lentiviral-transduced GBM gliomaspheres induced the
development of massive infiltrative gliomas in nude
mice after 2.5 months (Figure 3A). These tumors ex-
pressed GLI1, SHH, and PTCH1 (Figure S7), consistent
with the expression of these genes in gliomas by in
situ hybridization [7]. Using a protocol with 104 GFP-
lentiviral-transduced gliomasphere cells injected into
the striatum and left for 2 weeks prior to treatment for
an additional 2 weeks, we showed that cyclopamine
had a beneficial effect. Systemic intraperitoneal (i.p.)
treatment with cyclopamine, but not with carrier alone,
reduced glioma tumor volume (Figure 3B) and cell pro-
liferation (Figure 3C). Similar effects were seen with
subcutaneous xenografts of U87 glioma cells: Delivery
of cyclopamine in and around the tumor inhibited all
growth, and the tumors disappeared (Figures 3I, 3J,
and 3L), showing a size differential with controls as
soon as the second day of treatment.
Similar results were obtained after the cell-autono-
mous knockdown of SMOH. LV-shSMOH reducedSMOH mRNA levels by 65%–85% in U87 and GBM-8
cells, reduced GLI1 levels by w45% in both, markedly
reduced tumor volume, and reduced BrdU incorporation
2–3-fold (Figures 3D, 3F, 3G, 3J, 3K, and 3M and data not
shown). To further control any differences between the
experimental and control injected cells, including inser-
tion sites, we rendered LV-shSMOH silent and condi-
tionally inducible by treatment with doxycycline (DOX)
through cotransduction with LV-tTR-KRAB [12]. Two
weeks after intracranial injection of 104 cotransduced
GBM-8 cells (at >90% transduction efficiency), one half
of the mice were treated with DOX for an additional
2 weeks, and the other half were left untreated. DOX
treatment, inducing the silencing of SMOH, reduced
tumor volume by w80% as compared with mice that
did not receive DOX (Figure 3E). Long-term analysis
of straight LV-shSMOH and LV-control-transduced
GBM-8 cells demonstrated the greater survival of
LV-shSMOH-harboring mice versus LV-control mice
(Figure 3H).
The stemness signature of grade III gliomas but not of
most GBMs contrasts with the ability of both to form
gliomaspheres. If GBM cancer stem cells are simply
less abundant than those in grade III tumors, the selec-
tion of cancer stem cells in gliomasphere cultures could
yield a similar enrichment. The expression patterns of
25 selected genes in seven gliomasphere cultures (Fig-
ures 1A and 4A and Figure S8) identified a subgroup of
genes displaying expression within a 2-fold variation
from the mean, or overexpression, in all spheres. This
included GLI1, PTCH1, NANOG, OCT4, SOX2, BMI1,
and PCNA. The latter indicated similar proliferation of
all sphere cultures. Different gliomaspheres therefore
have active GLI1 function and might have similar num-
bers of cancer stem cells, assuming similar expression
per cell.
To test for a link between HH-GLI signaling and stem-
ness, we quantified the ability of dissociated, single-
gliomasphere cells to generate secondary spheres as
a measure of self-renewal (Figures 4B and 4E). Treat-
ment of dissociated gliomasphere cells with cyclop-
amine for 7 days, prior to renewed dissociation and
cloning without the drug, resulted in a reduction of
w50%–65% in clones as compared to tomatidine treat-
ment (Figure 4C). Because 7 days allows for approxi-
mately five cell divisions (calculated from BrdU incorpo-
ration data), giving rise to a 32-cell gliomasphere derived
from a single cell (assuming constant division rates), and
the cloning rate was at 6%–7%, there are on average
two clonogenic stem cells per 32-cell sphere. Given
that cyclopamine treatment for 7 days also decreased
sphere volume—but not cell size—byw50% (Figure 4B),
as it also affected growth, we deduced that cyclopamine
treatment reduced the number of cancer stem cells to
0.3–0.5 per sphere on average, thus rendering them
nonviable, consistent with the lack of recovery after
long-term cyclopamine treatment (Figure S6E). Tran-
sient inhibition of SMOH (with DOX) for 7 days prior tonot shown for histograms denoting ratios, but significance is provided by asterisks (p < 0.05). PC denotes pineocytoma, and NC denotes
neurocytoma.
(E and F) Rescue of the effects of cyclopamine by siRNA GLI3. The incompleteness of the effect is likely due to partial siRNA lipofection compared
with the ubiquitous effects of the drug.GLI1 orGLI2 siRNAs did not rescue the effects of cyclopamine (not shown). Asterisks denote significative
(p < 0.05) changes.
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168Figure 2. Requirement of HH-GLI Function in Glioma Stem Cell Cultures and Combined Effects with Temozolomide
(A and B) Phase-contrast and fluorescent images after immunolabeling with glial fibrillary acidic protein (GFAP; green) and Nestin (red)
antibodies, respectively, of GBM-8 gliomaspheres. The scale bar represents 140 mm.
(C–E) Decrease in cell proliferation as measured by BrdU incorporation (C and E) or increase in apoptosis measured by activated Caspase-3+ (D)
in gliomaspheres treated with cyclopamine (Cyc) or tomatidine (Tom) (C and D) or transduced with LV-control or LV-shSMOH (E).
(F and G) Synergistic or additive effects of intermediate doses of cyclopamine and TMZ on inhibition of cell proliferation and apoptosis as
measured by phospho-Histone3+ (F) or Caspase3+ labeling (G), respectively. All combinations are significantly more effective (p < 0.05; asterisks)
as compared with cyclopamine alone, and all but OG-III-1 (F) are more effective as compared with TMZ alone (p < 0.05).cloning mimicked the results obtained with cyclopamine
(Figure 4D). Similar treatment with recombinant SHH, in
contrast, increased the number of clones by w145%–
240% (Figure S9A). Because SHH treatment increased
sphere volume w3–4-fold on average (Figure 4B), it in-
duced an increase in the number of glioma stem cells
to w10–20 per sphere. Similar experiments with TMZ
showed that it does not significantly affect cancerstem cell self-renewal (p = 0.3, 50 mM TMZ versus treat-
ment with dimethyl sulfoxide [DMSO] carrier alone).
We used CD133 expression to purify glioma-initiating
cancer stem cells by fluorescence- and magnetic-acti-
vated cell sorting (FACS, MACS) [5, 6] (Figure 4E). The
percentage of secondary clones from CD133+ MACS-
sorted GBM-8 cells was 40-fold higher as compared
with CD1332 cells. The percentage of secondary
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169Figure 3. Inhibition of Human Glioma Xenograft Growth In Vivo by Interference with HH-GLI Signaling
(A) Development of invasive gliomas after intracerebral implantation of gliomaspheres transduced with a lentiviral vector expressing LacZw1
month after implantation of 105 cells (n = 7 mice for GBM-8, n = 7 mice for GBM-7, and n = 7 mice for OG-III-1, not shown). Glioma stem cell-
derived tumor cells infiltrate into the parenchyma (cells are blue after X-Gal cytochemistry).
(B and C) Inhibition of intracraneal tumor growth after treatment with cyclopamine (n = 3 mice for OG-III-1, and n = 3 mice for GBM-8, not shown)
but not carrier alone (n = 3 mice for OG-III-1, and n = 3 mice for GBM-8, not shown). Tumor volume (B) and BrdU+ cell number (C) were monitored
in section reconstructions.
(D) Tumor volume was also decreased after LV-shSMOH transduction (n = 3 mice) but not after LV-control transduction (n = 3 mice).
(E) Infection with GBM-8 gliomasphere cells with LV-shSMOH and LV-tTR-KRAB (see Supplemental Data) reduced tumor volume only after
induction by DOX (n = 3 mice with DOX treatment and 3 mice without).
(F and G) Representative examples of intracraneal gliomasw1 month after implantation of 104 GFP+ gliomapsheres treated as described. The
asterisks denote the injection sites. Note the strong migration of tumor cells contralaterally along the corpus callosum (cc, arrow) in control (G)
but not LV-shSMOH-expressing (G) cases.
(H) Survival of mice harboring LV-control (n = 4) or LV-shSMOH-transduced (n = 4) cells. Mice were sacrificed at the first signs of terminal disease,
before extreme pain was apparent.
(I–M) Inhibition of subcutaneous U87 gliomas by injection of cyclopamine ([I and L]; n = 8 tumors) or interference with SMOH (LV-shSMOH;
[J, K, and M]; n = 6 tumors), but not in U87 tumors treated with carrier alone ([I] and not shown; n = 8 tumors) or infected with LV-control
([J and M]; n = 6 tumors). Asterisks denote significative changes (p < 0.05).
The scale bar represents 0.25 cm in (A), 0.8 mm in (F) and (G), and 8 mm in (J)–(L).spheres from four gliomasphere cultures was on aver-
age 2.3-fold lower than the percentage of FACS-sorted
CD133+ cells (Figure S10B), raising the possibility that
not all CD133+ cells are cancer stem cells as determinedby clonogenic behavior, consistent with the variability of
CD133 expression (Figures 1A and 4A). Analysis of
a subset of genes in CD133+ versus CD1332 cells
showed that SHH was enriched in all samples, whereas
Current Biology
170Figure 4. Effects of HH-GLI Signaling on Self-Renewal and on CD133+ Glioma Cancer Stem Cells
(A) Profile of the expression of selected genes in seven gliomasphere stem cell cultures. White denotes normal expression within 2-fold up and
50% down of the average of all values per gene without counting the outliers; red denotes >2-fold overexpression; and light blue denotes <2-fold
underexpression (Figure S8). Boxed and highlighted are stemness genes that show normalcy in all samples, or enhanced expression likeGLI1 and
PTCH1.
(B) Representative image of gliomaspheres (GBM-8) treated with cyclopamine (top), tomatidine (middle), or SHH (bottom) for 7 days in a cloning
assay. The scale bar represents 80 mm.
(C and D) Reduction of the number of secondary gliomaspheres, as a measure of self-renewal, after interference with SMOH function through
treatment with cyclopamine (C) or RNA interference (D). Ratios are shown as percentage of reduction. Asterisks denote significative changes
(p < 0.05) over controls as indicated.
(E) Schematic diagram of the dissociation, FACS/MACS analyses, treatment, and cloning methods used to determine the self-renewal properties
and expression profile of CD133+ cells (see [F]–[H]).
(F) Inhibition of clonogenicity of CD133+ cells isolated from three glioma stem cell cultures and one fresh tumor. Ratios are cyc/tom, and asterisks
denote significative changes (p < 0.05).
(G) Gene-expression changes in gliomaspheres derived from CD133+ cells treated for 7 days with cyclopamine or tomatidine used in (F). Changes
are shown as cyc/tom ratios, and columns show the decrease in gene expression. For example, in GMB-7, GLI1 is reduced to 5% of its normal
expression. Note that the expression of GFAP, NCAM, EGFR, DOUBLECORTIN (DCX), and BCAN is not altered.
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171NOTCH1 was enriched in all efficient cultures (Figures
S10A and S10B). There was also a correlation between
efficiency of sphere formation (quality) and stemness-
marker expression (Figure S10).
Cyclopamine treatment of CD133+ cells for 7 days
prior to cloning without the drug (see Figure 4E) reduced
the number of clones by w20%–45% (Figure 4F). This
result was observed in sphere cultures after several pas-
sages as well as in CD133+ cells freshly purified from
a patient’s GBM (Figure 4F). Conversely, SHH treat-
ment increased secondary-sphere formation by 120%–
140% (Figure S9B). The clonogenicity decrease result-
ing from inhibition of endogenous HH-GLI signaling
was correlated with a coordinated decrease in GLI1,
PTCH1, and SHH expression at the time of cloning, but
also with the specific and coordinated downregulation
of stemness-gene expression (Figure 4G). Treatment
of freshly MACS-sorted CD133+ cells with cyclopamine
for only 4 hr resulted in a decrease in GLI1, PTCH1,
NANOG, SOX2, and OCT4 expression by 50%, 40%,
10%, 57%, and 20% for GBM-8 (and in GMB-6, not
shown), respectively, as compared with cyclopamine-
treated CD1332 cells, strongly suggesting the direct
inhibition of HH-GLI signaling by cyclopamine and the
regulation of stemness genes by this pathway.
Here, we demonstrate that human gliomas and their
cancer stem cells require HH-GLI pathway activity for
proliferation, survival, self-renewal, and tumorigenicity.
The widespread expression ofGLI1 in gliomas is consis-
tent with its isolation from a glioma cell line [13] and its
expression in brain tumors in situ [7]. The discrepancy
with previous work, suggesting that GLI1 was not over-
expressed in gliomas [14], can be partly explained by the
fact that the cerebellum, which we now know expresses
GLI1 at the highest levels [15], was used as the baseline.
We have also uncovered a stemness signature that we
interpret to denote the abundance of cancer stem cells
in grade III gliomas. Cancer stem cells in GBMs may
become diluted by the increased number of more differ-
entiated tumor-derived cells, which gives them their
multiforme character, and by the enhanced participation
of nontumor cells in GBMs, for instance through in-
creased angiogenesis. Interestingly, angiogenesis in gli-
omas could not only provide required nutrients to the tu-
mor but also enhance its growth and cancer stem cell
self-renewal in cases when new vessels express SHH.
Whereas glioma cancer stem cells express markers of
endogenous stem cells [4, 16, 17], the origin of the for-
mer is unclear. They could arise through a dedifferentia-
tion process or derive from precursors or endogenous
brain stem cells [16, 18–20]. Paralleling the derivation
of medulloblastomas from SHH-dependent GLI1+ corti-
cal cerebellar cells [7, 15, 21], glioma and other cancer
stem cells could derive from endogenous GLI1+ cells, in-
cluding those found in stem cell niches [7, 15, 22–25].
Our results argue for the development of antagonists
of GLI1,2 and agonists of GLI3R as anticancer agents.
Given that cyclopamine induces both of these changes
simultaneously and shows additive and synergistic
effects with TMZ, a combinatorial approach with these
agents may be advantageous to the treatment of the
tumor bulk and its cancer stem cells. The findings that
HH-GLI signaling is involved in regulating the prolifera-
tion of both endogenous brain stem cells [22–25] andglioma cancer stem cells (this work), and the lack of
obvious secondary effects in cyclopamine-treated adult
mice ([23, 26], this work), allow us to suggest that such
treatments may spare normal quiescent stem cells in
their niches, likely allowing regeneration of any damage
to normal adult tissues after cessation of treatment.
Supplemental Data
Supplemental Data include Experimental Procedures, ten figures,
and one table and are available with this article online at: http://
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Note Added in Proof
This version of the paper differs slightly from the one published orig-
inally online because a minor error in the labeling of Figure 4E has
been corrected here. See the Erratum for more details.
